Article thumbnail
Location of Repository

Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo

By Wei Shen, Chun-Yi Wang, Xue-Hu Wang and Zhong-Xue Fu
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2703625
Provided by: PubMed Central

Suggested articles

Citations

  1. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med
  2. (2004). Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther
  3. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science
  4. (2006). Bapat B: Cyclooxygenase-2 knockdown by RNA interference in colon cancer.
  5. (2002). Breakthrough of the year. Small RNAs make big splash.
  6. (2004). C: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol
  7. (2007). Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study.
  8. (2003). Cl: Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res
  9. (1997). DC: A noble anti-apoptotic gene, Survivin,
  10. (2008). Deng C: Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Int Immunopharmacol
  11. (1999). DH: Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res
  12. (1997). DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med
  13. (2008). et al.: Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice. Hepatology
  14. (2004). et al.: Use of siRNAs and antisense oligonucleotides against Survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides
  15. (2008). Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther
  16. Global cancer statistics,
  17. (2006). Grossman D: Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene
  18. (2004). Haim N: Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. Med Oncol
  19. (1999). JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res
  20. (2008). L: Surgical resection of a solitary pancreatic metastasis from colorectal cancer: a new step to a cure? Clin Colorectal Cancer
  21. (2008). Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology
  22. (2005). MG: Survivin as a target for new anticancer interventions.
  23. (2006). PS: Structural, functional and therapeutic biology of Survivin. Cancer Lett.
  24. (2005). Ruers T: Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases.
  25. (2008). S: Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer
  26. (2008). Shiau AL: Conditionally replicating E1Bdeleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Ther
  27. (2009). Sun XQ: Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther
  28. (2006). Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther
  29. (2008). Thun MJ: Cancer statistics,
  30. (2009). Wang YG: Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carring MDA-7/IL-24. Acta Pharmacol Sin
  31. (2003). XY: An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res
  32. (2007). Zhang X: Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.